XML 44 R29.htm IDEA: XBRL DOCUMENT
v3.22.4

BUSINESS COMBINATIONS (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2022
BUSINESS COMBINATIONS |
Schedule of unaudited pro forma information | ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year Ended | ​ | Fiscal Year Ended
​ | ​ | September 30, 2022 | ​ | September 30, 2021
Total revenues | ​ | $ | 593,622 | ​ | $ | 454,208
​ | ​ | ​ |  | ​ | ​ |
Net (loss) income | ​ | $ | (141,601) | ​ | $ | 10,859
HistoTox Labs |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​
Accounts receivable | ​ | ​ | 977
Unbilled revenues | ​ | ​ | 337
Operating lease right of use ("ROU") asset | ​ | ​ | 2,239
Property and equipment | ​ |  | 3,929
Intangible assets | ​ | ​ | 8,300
Goodwill | ​ | ​ | 9,339
Accounts payable | ​ | ​ | (150)
Accrued expenses | ​ | ​ | (136)
Customer advances | ​ | ​ | (207)
Operating lease liability | ​ |  | (2,239)
​ | ​ | $ | 22,389
Bolder BioPATH |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Accounts receivable | ​ | ​ | 2,146
Unbilled revenues | ​ | ​ | 1,798
Operating lease ROU asset | ​ | ​ | 2,750
Property and equipment | ​ |  | 6,523
Intangible asset | ​ | ​ | 12,700
Other assets | ​ | ​ | 34
Goodwill | ​ | ​ | 36,206
Accounts payable | ​ | ​ | (153)
Accrued expenses | ​ |  | (243)
Deferred revenue | ​ | ​ | (662)
Deferred tax liability | ​ | ​ | (4,867)
Operating lease liability | ​ |  | (2,750)
​ | ​ | $ | 53,482
Gateway Pharmacology Laboratories LLC |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Accounts receivable | ​ | ​ | 409
Operating lease ROU asset | ​ | ​ | 120
Property and equipment | ​ |  | 359
Intangible asset | ​ | ​ | 100
Other assets | ​ | ​ | 4
Goodwill | ​ |  | 2,260
Accounts payable | ​ | ​ | (3)
Accrued expenses | ​ | ​ | (72)
Deferred tax liability | ​ | ​ | (171)
Operating lease liability | ​ |  | (120)
​ | ​ | $ | 2,886
BioReliance Corporation |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Property and equipment | ​ | ​ | 175
Intangible asset | ​ |  | 640
​ | ​ | $ | 815
Plato BioPharma Inc |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Cash | ​ | ​ | 1,027
Trade receivables and contract assets | ​ | ​ | 853
Prepaid expenses and other assets | ​ | ​ | 133
Property and equipment | ​ | ​ | 1,127
Operating lease right-of-use assets, net | ​ | ​ | 2,272
Goodwill | ​ | ​ | 9,279
Intangible assets | ​ | ​ | 4,800
Accounts payable | ​ | ​ | (113)
Accrued expenses and other liabilities | ​ | ​ | (343)
Operating lease liabilities | ​ | ​ | (2,272)
Deferred tax liabilities | ​ | ​ | (1,457)
​ | ​ | $ | 15,306
Envigo RMS Holding Corp |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Cash | ​ | ​ | 2,488
Restricted cash | ​ | ​ | 435
Trade receivables and contract assets | ​ | ​ | 43,566
Inventories | ​ | ​ | 40,000
Prepaid expenses and other current assets | ​ | ​ | 17,373
Property and equipment | ​ | ​ | 106,338
Operating lease right-of-use assets, net | ​ | ​ | 13,229
Goodwill | ​ | ​ | 282,768
Intangible assets - customer relationships | ​ | ​ | 251,000
Intangible assets - intellectual property | ​ | ​ | 49,000
Other assets | ​ | ​ | 7,676
Accounts payable | ​ | ​ | (25,832)
Accrued expenses and other liabilities | ​ | ​ | (11,665)
Fees invoiced in advance | ​ | ​ | (7,047)
Current portion on long-term operating lease | ​ |  | (4,371)
Long-term operating leases, net | ​ | ​ | (8,634)
Other liabilities | ​ | ​ | (5,339)
Deferred tax liabilities | ​ | ​ | (77,291)
Noncontrolling interest | ​ | ​ | 880
​ | ​ | $ | 674,574
Schedule of information related to measurement assumptions | ​
​ | ​ | ​ | ​ | ​
Stock price | ​ | $ | 53.31 | ​
Strike price | ​ | $ | 9.93 | ​
Volatility | ​ | ​ | 75.93 | %
Expected term | ​ | ​ | 3.05 | ​
Risk-free rate | ​ | ​ | 0.62 | %
Robinson Services, Inc. |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Customer relationship | ​ | ​ | 4,700
Non-compete agreement | ​ | ​ | 300
Supply agreement | ​ | ​ | 200
Goodwill | ​ | ​ | 948
​ | ​ | $ | 6,148
Integrated Laboratory Systems, LLC (ILS) |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Cash | ​ | ​ | 797
Trade receivables, contract assets and other current assets | ​ | ​ | 4,730
Property and equipment | ​ | ​ | 4,436
Operating lease right-of-use assets, net | ​ | ​ | 4,994
Goodwill | ​ | ​ | 25,283
Intangible assets | ​ | ​ | 22,300
Accounts payable | ​ | ​ | (1,165)
Accrued expenses and other liabilities | ​ | ​ | (905)
Fees invoiced in advance | ​ | ​ | (2,472)
Operating lease liabilities | ​ | ​ | (4,554)
​ | ​ | $ | 53,444
Orient BioResource Center, Inc |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | ​
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Cash | ​ | ​ | 5,481
Trade receivables and contract assets | ​ | ​ | 2,025
Inventories | ​ | ​ | 9,400
Prepaid expenses and other current assets | ​ | ​ | 2,609
Property and equipment | ​ | ​ | 8,336
Goodwill | ​ | ​ | 18,624
Intangible assets | ​ | ​ | 13,400
Accounts payable | ​ | ​ | (552)
Accrued expenses and other liabilities | ​ | ​ | (285)
Fees invoiced in advance | ​ | ​ | (6,548)
Deferred tax liabilities | ​ | ​ | (3,216)
​ | ​ | $ | 49,274
Protypia, Inc. |
BUSINESS COMBINATIONS |
Schedule of purchase price allocation | ​
​ | ​ | ​ | ​
​ | ​ | Preliminary
​ | ​ | Allocation as of
​ | ​ | September 30, 2022
Assets acquired and liabilities assumed: |  | ​ |
Other assets, net | ​ | ​ | 50
Goodwill | ​ | ​ | 3,305
Intangible assets | ​ | ​ | 9,600
Deferred tax liabilities | ​ |  | (2,089)
​ | ​ | $ | 10,866

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(3) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionProFormaInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_HistotoxLabsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_BolderBioPTHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_GatewayPharmacologyLaboratoriesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_BioRelianceCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_PlatoBiopharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_EnvigoRmsHoldingCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_RobinsonServicesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_IntegratedLaboratorySystemsLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_OrientBioresourceCenterIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=notv_ProtypiaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |